209860-88-8
209860-88-8 structure
- Name: Tafluprost acid
- Chemical Name: 7-[2-(3,3-difluoro-4-phenoxybut-1-enyl)-3,5-dihydroxycyclopentyl]hept-5-enoic acid
- CAS Number: 209860-88-8
- Molecular Formula: C22H28F2O5
- Molecular Weight: 410.452
- Catalog: Signaling Pathways GPCR/G Protein Prostaglandin Receptor
- Create Date: 2018-05-02 08:00:00
- Modify Date: 2024-01-03 06:16:40
-
Tafluprost acid (AFP-172), an active metabolic form of Tafluprost, is a selective prostanoid FP receptor agonist. Tafluprost acid shows a high affinity for human prostanoid FP receptor with Ki and EC50 values of 0.4 nM and 0.53 nM, respectively. Tafluprost acid has 126 times weaker binding affinity for prostanoid EP3 receptor (IC50=67 nM) than for the prostanoid FP receptor. Tafluprost acid can be used in the research of glaucoma[1][2][3].
| Name | 7-[2-(3,3-difluoro-4-phenoxybut-1-enyl)-3,5-dihydroxycyclopentyl]hept-5-enoic acid |
|---|---|
| Synonyms |
(5Z)-7-{(1R,2R,3R,5S)-2-[(1E)-3,3-Difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl}-5-heptenoic acid
5-Heptenoic acid, 7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-, (5Z)- tafluprost acid |
| Description | Tafluprost acid (AFP-172), an active metabolic form of Tafluprost, is a selective prostanoid FP receptor agonist. Tafluprost acid shows a high affinity for human prostanoid FP receptor with Ki and EC50 values of 0.4 nM and 0.53 nM, respectively. Tafluprost acid has 126 times weaker binding affinity for prostanoid EP3 receptor (IC50=67 nM) than for the prostanoid FP receptor. Tafluprost acid can be used in the research of glaucoma[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
Human FP Receptor:0.4 nM (Ki) Human FP Receptor:0.53 nM (EC50) EP3 Receptor:67 nM (IC50) |
| In Vitro | Tafluprost acid (10, 100 nM, added on days 0 and 2) significantly inhibits adipogenesis in the early and late stages of differentiation of 3T3-L1 preadipocytes[2]. Tafluprost acid (100 nM, added on day 2 after initiating differentiation) suppresses adipogenesis in wild-type but not in FP knockout mouse primary adipocytes[2]. Tafluprost acid (10-4 M, 6 hours) stimulates the proliferation, migration of human umbilical vascular endothelial cells (HUVECs)[4]. Tafluprost acid (10-4 M, 4-18 hours) stimulates the tube formation of HUVECs[4]. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 575.9±50.0 °C at 760 mmHg |
| Molecular Formula | C22H28F2O5 |
| Molecular Weight | 410.452 |
| Flash Point | 302.1±30.1 °C |
| Exact Mass | 410.190491 |
| PSA | 86.99000 |
| LogP | 2.80 |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.579 |
|
~%
209860-88-8 |
| Literature: DR.REDDYS LABORATORIES LIMITED; JACKSON, Mark P Patent: WO2013/118058 A1, 2013 ; Location in patent: Page/Page column 10-11 ; |
|
~%
209860-88-8 |
| Literature: DR.REDDYS LABORATORIES LIMITED; JACKSON, Mark P Patent: WO2013/118058 A1, 2013 ; |
|
~%
209860-88-8 |
| Literature: DR.REDDYS LABORATORIES LIMITED; JACKSON, Mark P Patent: WO2013/118058 A1, 2013 ; |
|
~%
209860-88-8 |
| Literature: EVERLIGHT USA, INC.; TSAI, Chia-Chung; CHEN, Chien-Yuh; LIANG, Sen-Bau; LO, Yu-Chi; YAO, Chi-Hsiang Patent: US2014/51882 A1, 2014 ; |
|
~%
209860-88-8 |
| Literature: EVERLIGHT USA, INC.; TSAI, Chia-Chung; CHEN, Chien-Yuh; LIANG, Sen-Bau; LO, Yu-Chi; YAO, Chi-Hsiang Patent: US2014/51882 A1, 2014 ; |
|
~%
209860-88-8 |
| Literature: EVERLIGHT USA, INC.; TSAI, Chia-Chung; CHEN, Chien-Yuh; LIANG, Sen-Bau; LO, Yu-Chi; YAO, Chi-Hsiang Patent: US2014/51882 A1, 2014 ; |
| Precursor 6 | |
|---|---|
| DownStream 0 | |